New Zealand - English - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - butyl aminobenzoate picrate 1%; nitromersol 1:5000 - topical ointment - 1%/1:5000 - active: butyl aminobenzoate picrate 1% nitromersol 1:5000

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;  ;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections

United States - English - NLM (National Library of Medicine)

buddate co ltd - butylene glycol (unii: 3xus85k0ra) (butylene glycol - unii:3xus85k0ra), inonotus obliquus fruiting body (unii: mro1fs760m) (inonotus obliquus fruiting body - unii:mro1fs760m), glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - butylene glycol 6.03 g in 100 g - moisturizer & skin conditionnig (protectant) 1. after facial wash, cares the skin texture lightly with toner and take the mask sheet out and unfold it to put on the face to be fit. 2. leave the sheet about 10~20 minutes and take a rest and remove the sheet and tap the essence left on skin to have it sufficiently absorbed..

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - fluazifop-p-butyl - unknown - fluazifop-p-butyl phenoxy acids-propionics active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sinon australia pty limited - fluazifop-p-butyl - unknown - fluazifop-p-butyl phenoxy acids-propionics active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - fluazifop-p-butyl - unknown - fluazifop-p-butyl phenoxy acids-propionics active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - fluazifop-p-butyl - unknown - fluazifop-p-butyl phenoxy acids-propionics active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

shandong binnong technology co ltd - fluazifop-p-butyl - unknown - fluazifop-p-butyl phenoxy acids-propionics active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agbitech pty ltd - butyl salicylate - unknown - butyl salicylate phenol active 0.0 - active constituent

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime   excipient: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: · severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns.